Drugs / AUS-131
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02352025 | Apr 2015 → Apr 2019 | breast cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT02142777 | Jul 2014 → Apr 2016 | Alzheimer disease | Russell Swerdlow, MD | Completed | No outcome recorded |
| Phase 1 | NCT00998920 | Dec 2008 → Apr 2009 | — | Ausio Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00787007 | Sep → Dec 2008 | — | Ausio Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03101085 | May 2017 → Mar 2021 | Alzheimer disease | Russell Swerdlow | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07194590 | Feb 2026 → Nov 2030 expected | chronic kidney disease | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT05741060 | Jun 2023 → Oct 2026 expected | arteriosclerosis disorder, cognitive disorder | Akira Sekikawa | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06128278 | Mar 2023 → Dec 2026 expected | chronic kidney disease | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT00962585 | Jun 2010 → Nov 2011 | — | Ausio Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00962390 | Jun 2009 → Jan 2016 | benign prostatic hyperplasia | Ausio Pharmaceuticals, LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01301586 Comparator | Nov 2010 → Sep 2011 | acne | Nexgen Dermatologics, Inc. | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUS-131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL198877 ↗ |
| Known as | Equol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07194590 ↗ |
| Known as | S-equol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02352025 ↗ |
| Known as | S-equol is also called AUS-131 | “S-equol is also called AUS-131” NCT03101085 ↗ |
| Action | Activate | “S-equol, a compound that acts like estrogen in the body” NCT02142777 ↗1“Estrogen receptor beta agonist” CHEMBL198877 ↗ |
| Modality | Small molecule | — CHEMBL198877 ↗ |
| Route | Oral | “capsule, oral, single dose” NCT00787007 ↗ |
| Target | ESR2 | “Estrogen receptor beta agonist” CHEMBL198877 ↗ |